
CAS Number144494-65-5
SynonymsTirofiban [BAN:INN]; N-(Butylsulfonyl)-O-[4-(piperidin-4-yl)butyl]-L-tyrosine; N-(n-butanesulfonyl)-O-(4-(4-piperidinyl)butyl)-(S)-tyrosine; MFCD05237246; 2-S-(n-Butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]propionic acid; (S)-2-(butane-1-sulfonylamino)-3-[4-(4-piperidin-4-yl-butoxy)phenyl]-propionic acid; Agrastat; Agrastat (TN); N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid; UNII-GGX234SI5H; Aggrastat; Tirofiban; Tirofiban (INN); (2S)-2-(butane-1-sulfonamido)-3-{4-[4-(piperidin-4-yl)butoxy]phenyl}propanoic acid; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; L700462; MK383
Molecular FormulaC22H36N2O5S
Molecular Weight440.60
Purity≥98.5 (HPLC)%
Density1.2±0.1 g/cm3
Boiling Point611.7±65.0 °C at 760 mmHg
Melting Point223-225ºC
Appearancepowder
Symbol
Signal WordWarning
Please Login or Create an Account to: See VlP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 144494-65-5 |
| Catalog No. | 2A-9012751 |
| Chinese Name | 替罗非班 |
| Synonyms | Tirofiban [BAN:INN]; N-(Butylsulfonyl)-O-[4-(piperidin-4-yl)butyl]-L-tyrosine; N-(n-butanesulfonyl)-O-(4-(4-piperidinyl)butyl)-(S)-tyrosine; MFCD05237246; 2-S-(n-Butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]propionic acid; (S)-2-(butane-1-sulfonylamino)-3-[4-(4-piperidin-4-yl-butoxy)phenyl]-propionic acid; Agrastat; Agrastat (TN); N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid; UNII-GGX234SI5H; Aggrastat; Tirofiban; Tirofiban (INN); (2S)-2-(butane-1-sulfonamido)-3-{4-[4-(piperidin-4-yl)butoxy]phenyl}propanoic acid; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; L700462; MK383 |
| Molecular Formula | C22H36N2O5S |
| Molecular Weight | 440.60 |
| Purity | ≥98.5 (HPLC) |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 611.7±65.0 °C at 760 mmHg |
| Melting Point | 223-225ºC |
| Appearance | powder |
| Storage Condition | -20°C |
| Packaging | II |
| Application | Tirofiban is a non-peptide, glycoprotein IIb/IIIa antagonist. |
| HTC | 2942000000 |
| PubChem ID | 329753339 |
| MDL Number | MFCD05237246 |
| SMILES | CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O |
| InChI | 1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1 |
| InChI Key | COKMIXFXJJXBQG-NRFANRHFSA-N |
| Beilstein/REAXYS | 6182267 |
| NACRES Code | NA.25 |
| UNSPSC | 12352106 |
| Hazard Symbols | 8 |
| MSDS | msds/12751_1_144494_65_5.pdf |
| Use of | Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonistTarget: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation. Tirofiban is an antithrombotic used in the treatment of unstable angina.Tirofiban, in a concentration-dependent manner reduced platelet aggregation evoked by ADP (IC50 approximately 70 ng/ml), collagen (IC50 approximately 200 ng/ml), and thrombin (IC50 approximately 5,000 ng/ml). Properties Name tirofiban Synonym More Synonyms Tirofiban Biological Activity Description Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonistTarget: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation. Tirofiban is an antithrombotic used in the treatment of unstable angina.Tirofiban, in a concentration-dependent manner reduced platelet aggregation evoked by ADP (IC50 approximately 70 ng/ml), collagen (IC50 approximately 200 ng/ml), and thrombin (IC50 approximately 5,000 ng/ml). Related Catalog Signaling Pathways >> Cytoskeleton >> Integrin Research Areas >> Cardiovascular Disease References [1]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46. [2]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100. [3]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. [4]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. [5]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53. Chemical & Physical Properties Molecular Formula C22H36N2O5S Exact Mass 440.234497 PSA 113.11000 Index of Refraction 1.532 InChIKey COKMIXFXJJXBQG-NRFANRHFSA-N Safety Information Hazard Codes Xi RIDADR UN3261 Packaging Group II Hazard Class 8 HS Code 2942000000 Synthetic Route Total: 1 Page N-Butylsulfonyl... CAS#:149490-61-9 CAS#:144494-65-5 Literature: Chung; Zhao; Hughes; Grabowski Tetrahedron, 1993 , vol. 49, # 26 p. 5767 - 5776 4-Picoline CAS#:108-89-4 CAS#:144494-65-5 Literature: Tetrahedron, , vol. 49, # 26 p. 5767 - 5776 Precursor & DownStream Precursor 2 CAS#:149490-61-9 N-Butylsulfonyl... CAS#:108-89-4 4-Picoline DownStream 0 |
| Transport Info | Product Name: Tirofiban |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Tipropidil | 70895-45-3 | 2A-9012746 |
| Tiprostanide | 67040-53-3 | 2A-9012747 |
| Tiprotimod | 105523-37-3 | 2A-9012748 |
| Tiquizium bromide | 71731-58-3 | 2A-9012749 |
| Tirilazad | 110101-66-1 | 2A-9012750 |
| Tirofiban hydrochloride monohydrate | 142373-60-2 | 2A-9012752 |
| Tisoquone | 40692-37-3 | 2A-9012753 |
| Tixadil | 2949-95-3 | 2A-9012754 |
| Tobicillin | 151287-22-8 | 2A-9012755 |
| Tocofenoxate | 61343-44-0 | 2A-9012757 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA